$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

$xers Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000186709622000127 Filed on November 09, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$33.14M	$29.73M	$11.00M
YoY Change	54.67%	170.23%	17.02%
Cost Of Revenue	$6.291M	$5.260M	$3.220M
YoY Change	28.68%	63.35%	13.7%
Gross Profit	$26.85M	$24.47M	$7.840M
YoY Change	62.35%	212.05%	18.5%
Gross Profit Margin	81.02%	82.3%	71.27%
Selling, General & Admin	$34.36M	$34.49M	$26.54M
YoY Change	-33.9%	29.98%	60.97%
% of Gross Profit	127.94%	140.98%	338.46%
Research & Development	$4.955M	$6.043M	$5.663M
YoY Change	-50.85%	6.71%	46.1%
% of Gross Profit	18.45%	24.7%	72.23%
Depreciation & Amortization	$3.077M	$2.711M	$323.0K
YoY Change	242.27%	739.32%	-15.0%
% of Gross Profit	11.46%	11.08%	4.12%
Operating Expenses	$42.02M	$40.53M	$32.20M
YoY Change	-32.88%	25.89%	58.14%
Operating Profit	-$15.17M	-$18.78M	-$24.36M
YoY Change	-67.07%	-22.9%	77.23%
Interest Expense	-$2.524M	$4.000M	$1.800M
YoY Change	46.23%	122.22%	-21.74%
% of Operating Profit
Other Income/Expense, Net	$4.426M	-$3.390M	-$1.651M
YoY Change	-658.13%	105.33%	-26.82%
Pretax Income	-$13.27M	-$22.17M	-$26.01M
YoY Change	-73.88%	-14.76%	62.56%
Income Tax	-$338.0K	-$339.0K	$0.00
% Of Pretax Income
Net Earnings	-$12.93M	-$21.83M	-$26.01M
YoY Change	-74.54%	-16.06%	62.56%
Net Earnings / Revenue	-39.01%	-73.44%	-236.45%
Basic Earnings Per Share		-$0.16	-$0.39
Diluted Earnings Per Share	-$0.10	-$0.16	-$391.1K
COMMON SHARES
Basic Shares Outstanding	136.0M shares	136.0M shares	66.50M shares
Diluted Shares Outstanding		136.0M shares	66.50M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$122.0M	$93.43M	$92.98M
YoY Change	19.07%	0.48%	-34.38%
Cash & Equivalents	$122.0M	$84.11M	$59.49M
Short-Term Investments	$0.00	$9.324M	$33.49M
Other Short-Term Assets	$9.287M	$7.847M	$3.582M
YoY Change	102.38%	119.07%	-3.19%
Inventory	$24.74M	$20.12M	$14.24M
Prepaid Expenses	$9.287M	$7.847M	$3.582M
Receivables	$30.83M	$27.52M	$13.56M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$186.8M	$148.9M	$124.4M
YoY Change	31.01%	19.74%	-23.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.516M	$5.751M	$6.682M
YoY Change	-16.76%	-13.93%	-3.16%
Goodwill	$22.86M	$22.86M
YoY Change	0.0%
Intangibles	$120.6M	$123.3M
YoY Change	-8.25%
Long-Term Investments
YoY Change
Other Assets	$4.730M	$2.170M	$211.0K
YoY Change	470.57%	928.44%	5.5%
Total Long-Term Assets	$157.7M	$154.1M	$6.893M
YoY Change	-2.51%	2135.57%	-4.26%
TOTAL ASSETS
Total Short-Term Assets	$186.8M	$148.9M	$124.4M
Total Long-Term Assets	$157.7M	$154.1M	$6.893M
Total Assets	$344.5M	$303.0M	$131.3M
YoY Change	13.2%	130.85%	-22.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.606M	$3.916M	$4.290M
YoY Change	-48.39%	-8.72%	-8.72%
Accrued Expenses	$36.79M	$37.71M	$22.96M
YoY Change	-25.06%	64.25%	10.37%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$73.62M	$68.56M	$37.29M
YoY Change	-6.86%	83.88%	38.09%
LONG-TERM LIABILITIES
Long-Term Debt	$187.1M	$138.5M	$87.71M
YoY Change	112.42%	57.91%	-26.54%
Other Long-Term Liabilities	$31.00K	$311.0K	$1.897M
YoY Change	-98.15%	-83.61%	-80.24%
Total Long-Term Liabilities	$31.00K	$311.0K	$1.897M
YoY Change	-98.15%	-83.61%	-98.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$73.62M	$68.56M	$37.29M
Total Long-Term Liabilities	$31.00K	$311.0K	$1.897M
Total Liabilities	$299.3M	$248.0M	$133.7M
YoY Change	43.13%	85.44%	-14.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$554.8M	-$541.8M	-$409.3M
YoY Change	20.58%	32.37%
Common Stock	$14.00K	$14.00K	$7.000K
YoY Change	7.69%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$45.19M	$55.04M	-$2.461M
YoY Change
Total Liabilities & Shareholders Equity	$344.5M	$303.0M	$131.3M
YoY Change	13.2%	130.85%	-22.97%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$12.93M	-$21.83M	-$26.01M
YoY Change	-74.54%	-16.06%	62.56%
Depreciation, Depletion And Amortization	$3.077M	$2.711M	$323.0K
YoY Change	242.27%	739.32%	-15.0%
Cash From Operating Activities	-$16.12M	-$17.75M	-$22.61M
YoY Change	-44.31%	-21.48%	33.08%
INVESTING ACTIVITIES
Capital Expenditures	$132.0K	-$176.0K	-$307.0K
YoY Change	-200.76%	-42.67%	-1635.0%
Acquisitions
YoY Change
Other Investing Activities	$9.300M	$6.885M	$18.81M
YoY Change	-74.68%	-63.4%	-131.0%
Cash From Investing Activities	$9.168M	$6.709M	$18.51M
YoY Change	-74.95%	-63.74%	-130.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	49.16M	-187.0K	1.000K
YoY Change	39224.8%	-18800.0%	-99.99%
NET CHANGE
Cash From Operating Activities	-16.12M	-17.75M	-22.61M
Cash From Investing Activities	9.168M	6.709M	18.51M
Cash From Financing Activities	49.16M	-187.0K	1.000K
Net Change In Cash	42.21M	-11.23M	-4.105M
YoY Change	442.41%	173.62%	-93.65%
FREE CASH FLOW
Cash From Operating Activities	-$16.12M	-$17.75M	-$22.61M
Capital Expenditures	$132.0K	-$176.0K	-$307.0K
Free Cash Flow	-$16.25M	-$17.58M	-$22.30M
YoY Change	-43.6%	-21.19%	31.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001867096
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40880
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Registrant Name EntityRegistrantName	XERIS BIOPHARMA HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-1082097
	dei	Entity Address Address Line1 EntityAddressAddressLine1	180 N. LaSalle Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chicago
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60601
	dei	City Area Code CityAreaCode	844
	dei	Local Phone Number LocalPhoneNumber	445-5704
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	XERS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135985090	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84109000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67271000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	9324000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	35162000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27518000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17456000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	20121000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	18118000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7847000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4589000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	148919000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	142596000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5751000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6627000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	22859000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	22859000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	123318000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131450000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2170000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	829000	usd
CY2022Q3	us-gaap	Assets Assets	303017000	usd
CY2021Q4	us-gaap	Assets Assets	304361000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3916000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8924000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37707000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	usd
CY2022Q3	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	19321000	usd
CY2021Q4	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	15041000	usd
CY2022Q3	xers	Accruedreturnsreserve Accruedreturnsreserve	7277000	usd
CY2021Q4	xers	Accruedreturnsreserve Accruedreturnsreserve	4000000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	337000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1987000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	68558000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79040000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	138507000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	88067000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	30100000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22531000	usd
CY2022Q3	xers	Supply Agreements Liability Noncurrent SupplyAgreementsLiabilityNoncurrent	0	usd
CY2021Q4	xers	Supply Agreements Liability Noncurrent SupplyAgreementsLiabilityNoncurrent	5991000	usd
CY2022Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6645000	usd
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6883000	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	3856000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4942000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	311000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1676000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	247977000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	209130000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135961552	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135961552	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124873316	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124873316	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	596903000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	555359000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-541840000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-460110000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-37000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	55040000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95231000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	303017000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304361000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29725000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11060000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77104000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28161000	usd
CY2022Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	5260000	usd
CY2021Q3	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	3220000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	16343000	usd
	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	8429000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6043000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5663000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16011000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15078000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34491000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26535000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	103388000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	71539000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2711000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8132000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	48505000	usd
CY2021Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	35418000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	143874000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	95046000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18780000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24358000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66770000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66885000	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	472000	usd
CY2021Q3	us-gaap	Interest Income Other InterestIncomeOther	66000	usd
	us-gaap	Interest Income Other InterestIncomeOther	735000	usd
	us-gaap	Interest Income Other InterestIncomeOther	243000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	3989000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	1798000	usd
	us-gaap	Interest Expense InterestExpense	10958000	usd
	us-gaap	Interest Expense InterestExpense	5384000	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9000	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-81000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1746000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-91000	usd
CY2022Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-118000	usd
CY2021Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	7569000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3390000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1651000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16046000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5050000	usd
CY2022Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-22170000	usd
CY2021Q3	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26009000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-82816000	usd
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-71935000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-339000	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1086000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21831000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26009000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-81730000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-71935000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	16000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-5000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-5000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-34000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	2000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21816000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26015000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81736000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-71967000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.60
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.11
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135951761	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135951761	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66497593	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66497593	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	135508203	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	135508203	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	64722552	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	64722552	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33761000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18411000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26925000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	32000	usd
CY2021Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	71782	shares
CY2021Q1	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	365000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2461000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-16000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	44387000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-27515000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	140000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2512000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	374000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	19888000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-26009000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	1000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3665000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-6000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-2461000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95231000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-33714000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	30000000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2080000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	8000	usd
CY2022Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	197257	shares
CY2022Q1	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	416000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3301000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-35000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	96455000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-26185000	usd
CY2022Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	1317	shares
CY2022Q2	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	3000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3152000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	510000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	14000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	73943000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-21831000	usd
CY2022Q3	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	19007	shares
CY2022Q3	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	28000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2941000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	15000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	55040000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-81730000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-71935000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1033000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	980000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8132000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-148000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-353000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1111000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	727000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9394000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8638000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1223000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-236000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	xers	Adjustment For Change In Fair Value Of Warrants AdjustmentForChangeInFairValueOfWarrants	1746000	usd
	xers	Adjustment For Change In Fair Value Of Warrants AdjustmentForChangeInFairValueOfWarrants	91000	usd
	xers	Adjustment For Change In Fair Value Of Contingent Value Rights AdjustmentForChangeInFairValueOfContingentValueRights	7569000	usd
	xers	Adjustment For Change In Fair Value Of Contingent Value Rights AdjustmentForChangeInFairValueOfContingentValueRights	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10062000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6686000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2758000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	386000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1960000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5144000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5008000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1173000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-12135000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	4650000	usd
	xers	Accruedtradediscountsandrebates Accruedtradediscountsandrebates	4280000	usd
	xers	Accruedtradediscountsandrebates Accruedtradediscountsandrebates	798000	usd
	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	3277000	usd
	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	272000	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-238000	usd
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	usd
	xers	Increase Decrease In Supply Agreement Liabilities IncreaseDecreaseInSupplyAgreementLiabilities	-5280000	usd
	xers	Increase Decrease In Supply Agreement Liabilities IncreaseDecreaseInSupplyAgreementLiabilities	0	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2258000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	62000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-86772000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66589000	usd
	xers	Proceeds Payments From Capital Expenditures ProceedsPaymentsFromCapitalExpenditures	-392000	usd
	xers	Proceeds Payments From Capital Expenditures ProceedsPaymentsFromCapitalExpenditures	-954000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	30784000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	25685000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	93100000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25293000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61362000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	30000000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27000000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	54000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	97295000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	43496000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4816000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	737000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	510000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	374000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	167000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	447000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	365000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	78317000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27122000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16838000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21894000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67271000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37598000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84109000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59492000	usd
	us-gaap	Interest Paid Net InterestPaidNet	7689000	usd
	us-gaap	Interest Paid Net InterestPaidNet	5350000	usd
	xers	Issuance Of Warrants For Loan Agreement IssuanceOfWarrantsForLoanAgreement	2080000	usd
	xers	Issuance Of Warrants For Loan Agreement IssuanceOfWarrantsForLoanAgreement	0	usd
	us-gaap	Nature Of Operations NatureOfOperations	Organization and nature of the business <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of business </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Xeris Biopharma Holdings, Inc. ("Xeris Biopharma" or the "Company") is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. The Company currently has three commercially available products: Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis, the first and only U.S. Food and Drug Administration ("FDA") approved therapy for primary periodic paralysis ("PPP"); and Recorlev, approved by the FDA in December 2021 for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation technology platforms, XeriSol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and XeriJect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On October 5, 2021, Xeris Pharmaceuticals, Inc. ("Xeris Pharma") acquired Strongbridge Biopharma plc ("Strongbridge"), a biopharmaceutical company commercializing therapies for rare diseases with significant unmet needs. Immediately following the acquisition and related transactions, both Xeris Pharma and Strongbridge became wholly-owned subsidiaries of Xeris Biopharma. The common stock of Xeris Pharma and the ordinary shares of Strongbridge were de-registered after completion of the Transactions (as defined below in Note 4). On October 6, 2021, Xeris Biopharma’s common stock, par value $0.0001 per share, commenced trading on the Nasdaq Global Select Market (“Nasdaq”) under the ticker symbol "XERS". See "Note 4 – Business combination" for a more detailed description of the Transactions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used herein, the "Company" or "Xeris" refers to Xeris Pharma when referring to periods prior to the acquisition of Strongbridge on October 5, 2021 and to Xeris Biopharma when referring to periods on or subsequent to October 5, 2021. Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, Gvoke Kit and Ogluo (glucagon).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred operating losses since inception and has an accumulated deficit of $541.8 million as of September 30, 2022. The Company expects to continue to incur net losses for at least the next 12 months beyond the issuance date of these consolidated financials. Based on the Company’s current operating plans, existing working capital at September 30, 2022, capital raised in the first quarter and access to the additional $50.0 million remaining from the Credit Agreement and Guaranty with Hayfin Services LLP, the Company believes that its cash resources are sufficient to sustain operations and capital expenditure requirements for at least the next 12 months from the issuance date of these condensed consolidated financial statements. If needed, the Company may elect to finance its operations through equity or debt financing along with revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that such funding may be available to the Company on acceptable terms, or at all, or that the Company will be able to successfully market and sell Gvoke, Keveyis and Recorlev. Market volatility resulting from the COVID-19 pandemic, and geopolitical instability resulting from the ongoing military conflict between Russia and Ukraine, rising interest rates, inflationary pressures, the tightening of lending standards or other factors could also adversely impact the Company's ability to access capital as and when needed. The issuance of equity securities may result in dilution to stockholders. If the Company raises additional funds through the issuance of additional debt, which may have rights, preferences and privileges senior to those of our common stockholders, the terms of the debt could impose significant restrictions on the Company's operations. The failure to raise funds as and when needed could have a negative impact on the Company's financial condition and ability to pursue its business strategies. If additional funding is not secured when required, the Company may need to delay or curtail its operations until such funding is received, which would have a material adverse impact on the business prospects and results of operations.</span></div>
CY2022Q3	xers	Number Of Commercially Available Products NumberOfCommerciallyAvailableProducts	3	commerciallyavailableproduct
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-541800000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	29725000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11060000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77104000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28161000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	xers	Available For Sale Securities Maturities Period AvailableForSaleSecuritiesMaturitiesPeriod	P0Y1M6D
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	9336000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	12000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	9324000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35169000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	35162000	usd
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6047000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5181000	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9380000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7442000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4694000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5495000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	20121000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	18118000	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1200000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1000000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10919000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10762000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5168000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4135000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5751000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6627000	usd
CY2022Q3	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	400000	usd
CY2021Q3	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	300000	usd
	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	1000000	usd
	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	1000000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8682000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	123318000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	550000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	131450000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2711000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10843000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10843000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10843000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	10293000	usd
CY2022Q3	xers	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	77785000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	123318000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10792000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19638000	usd
CY2022Q3	xers	Accrued Supply Liabilities Current AccruedSupplyLiabilitiesCurrent	6720000	usd
CY2021Q4	xers	Accrued Supply Liabilities Current AccruedSupplyLiabilitiesCurrent	6009000	usd
CY2022Q3	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	1287000	usd
CY2021Q4	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	595000	usd
CY2022Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3714000	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3237000	usd
CY2022Q3	xers	Accruedresearchcosts Accruedresearchcosts	1417000	usd
CY2021Q4	xers	Accruedresearchcosts Accruedresearchcosts	1998000	usd
CY2022Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3854000	usd
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6715000	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	3459000	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1413000	usd
CY2022Q3	xers	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	0	usd
CY2021Q4	xers	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	1839000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6464000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7644000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	37707000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	usd
CY2020Q3	xers	Convertible Notes Purchased Due To Exercise Of Underwriter Option ConvertibleNotesPurchasedDueToExerciseOfUnderwriterOption	11300000	usd
	xers	Principal Amount Of Convertible Notes Converted PrincipalAmountOfConvertibleNotesConverted	8400000	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2736591	shares
CY2020Q4	xers	Principal Amount Of Convertible Notes Converted Privately PrincipalAmountOfConvertibleNotesConvertedPrivately	30700000	usd
CY2020Q4	xers	Stock Issued During Period Shares Conversion Of Convertible Securities Privately Exchanged StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPrivatelyExchanged	10435200	shares
CY2020Q4	xers	Loss On The Convertible Note Exchange Transactions LossOnTheConvertibleNoteExchangeTransactions	2600000	usd
CY2022Q1	xers	Debt Instrument Maximum Amount Per Drawing DebtInstrumentMaximumAmountPerDrawing	10000000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	23000	usd
CY2022Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	4808000	usd
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2608000	usd
CY2022Q3	us-gaap	Long Term Debt LongTermDebt	138507000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	88067000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	47175000	usd
CY2022Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	usd
CY2022Q3	xers	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	100000000	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	147175000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	4000000	usd
	us-gaap	Interest Expense InterestExpense	11000000	usd
CY2022Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	400000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1200000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1200000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	1800000	usd
	us-gaap	Interest Expense InterestExpense	5400000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	94012	shares
CY2022Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	84109000	usd
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	9324000	usd
CY2022Q3	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	30100000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	67271000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	35162000	usd
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	22531000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1769000	usd
	xers	Contingent Consideration Classified As Equity Gain Loss ContingentConsiderationClassifiedAsEquityGainLoss	7600000	usd
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4714982	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1822000	shares
	xers	Leastamountofannualincreaseofsharesavailableforissuance Leastamountofannualincreaseofsharesavailableforissuance	386000	shares
CY2020Q4	xers	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Upon Option Exchange ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodUponOptionExchange	832907	shares
CY2020Q4	xers	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Upon Option Exchange ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledUponOptionExchange	1127906	shares
CY2020Q4	xers	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Upon Option Exchange Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodUponOptionExchangeWeightedAverageExercisePrice	4.09
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.57
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9818748	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11362336	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.86
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M13D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	175000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.10
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11228	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.69
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	74665	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	5.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1632695	shares
CY2022Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y10M28D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8720670	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.45
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M29D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9818748	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y10M28D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	5.63
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	2.94
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.29
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	77380000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2941000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3665000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9394000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8638000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	356000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1444000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4890000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6080000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	6232000	usd
CY2022Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	58378000	usd
CY2021Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	600000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2200000	usd
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1800000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	38826646	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22587111	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
xers-20220930_def.xml	Edgar Link	unprocessable
0001867096-22-000127-index-headers.html	Edgar Link	pending
0001867096-22-000127-index.html	Edgar Link	pending
0001867096-22-000127.txt	Edgar Link	pending
0001867096-22-000127-xbrl.zip	Edgar Link	pending
exh101amendedandrestated.htm	Edgar Link	pending
exh101amendedandrestated001.jpg	Edgar Link	pending
exh101amendedandrestated002.jpg	Edgar Link	pending
exh101amendedandrestated003.jpg	Edgar Link	pending
exh101amendedandrestated004.jpg	Edgar Link	pending
exh101amendedandrestated005.jpg	Edgar Link	pending
exh101amendedandrestated006.jpg	Edgar Link	pending
exh101amendedandrestated007.jpg	Edgar Link	pending
exh101amendedandrestated008.jpg	Edgar Link	pending
exh101amendedandrestated009.jpg	Edgar Link	pending
exh101amendedandrestated010.jpg	Edgar Link	pending
exh101amendedandrestated011.jpg	Edgar Link	pending
exh101amendedandrestated012.jpg	Edgar Link	pending
exh101amendedandrestated013.jpg	Edgar Link	pending
exh101amendedandrestated014.jpg	Edgar Link	pending
exh101amendedandrestated015.jpg	Edgar Link	pending
exh101amendedandrestated016.jpg	Edgar Link	pending
exh101amendedandrestated017.jpg	Edgar Link	pending
exh101amendedandrestated018.jpg	Edgar Link	pending
exh101amendedandrestated019.jpg	Edgar Link	pending
exh101amendedandrestated020.jpg	Edgar Link	pending
exh101amendedandrestated021.jpg	Edgar Link	pending
exh101amendedandrestated022.jpg	Edgar Link	pending
exh101amendedandrestated023.jpg	Edgar Link	pending
exh101amendedandrestated024.jpg	Edgar Link	pending
exh101amendedandrestated025.jpg	Edgar Link	pending
exh101amendedandrestated026.jpg	Edgar Link	pending
exh101amendedandrestated027.jpg	Edgar Link	pending
exh101amendedandrestated028.jpg	Edgar Link	pending
exh101amendedandrestated029.jpg	Edgar Link	pending
exh101amendedandrestated030.jpg	Edgar Link	pending
exh101amendedandrestated031.jpg	Edgar Link	pending
exh101amendedandrestated032.jpg	Edgar Link	pending
exh101amendedandrestated033.jpg	Edgar Link	pending
exh101amendedandrestated034.jpg	Edgar Link	pending
exh101amendedandrestated035.jpg	Edgar Link	pending
exh101amendedandrestated036.jpg	Edgar Link	pending
exh101amendedandrestated037.jpg	Edgar Link	pending
exh101amendedandrestated038.jpg	Edgar Link	pending
exh101amendedandrestated039.jpg	Edgar Link	pending
exh101amendedandrestated040.jpg	Edgar Link	pending
exh101amendedandrestated041.jpg	Edgar Link	pending
exh101amendedandrestated042.jpg	Edgar Link	pending
exh101amendedandrestated043.jpg	Edgar Link	pending
exh101amendedandrestated044.jpg	Edgar Link	pending
exh101amendedandrestated045.jpg	Edgar Link	pending
exh101amendedandrestated046.jpg	Edgar Link	pending
exh101amendedandrestated047.jpg	Edgar Link	pending
exh101amendedandrestated048.jpg	Edgar Link	pending
exh101amendedandrestated049.jpg	Edgar Link	pending
exh101amendedandrestated050.jpg	Edgar Link	pending
exh101amendedandrestated051.jpg	Edgar Link	pending
exh101amendedandrestated052.jpg	Edgar Link	pending
exh101amendedandrestated053.jpg	Edgar Link	pending
exh101amendedandrestated054.jpg	Edgar Link	pending
exh102amendmentno1tocred.htm	Edgar Link	pending
exh102amendmentno1tocred001.jpg	Edgar Link	pending
exh102amendmentno1tocred002.jpg	Edgar Link	pending
exh102amendmentno1tocred003.jpg	Edgar Link	pending
exh102amendmentno1tocred004.jpg	Edgar Link	pending
exh102amendmentno1tocred005.jpg	Edgar Link	pending
exh102amendmentno1tocred006.jpg	Edgar Link	pending
exh102amendmentno1tocred007.jpg	Edgar Link	pending
exh102amendmentno1tocred008.jpg	Edgar Link	pending
exh103redacted-pyramidla.htm	Edgar Link	pending
exh103redacted-pyramidla001.jpg	Edgar Link	pending
exh103redacted-pyramidla002.jpg	Edgar Link	pending
exh103redacted-pyramidla003.jpg	Edgar Link	pending
exh103redacted-pyramidla004.jpg	Edgar Link	pending
exh103redacted-pyramidla005.jpg	Edgar Link	pending
exh103redacted-pyramidla006.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
q32022exhibit311.htm	Edgar Link	pending
q32022exhibit312.htm	Edgar Link	pending
q32022exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xers-20220930.htm	Edgar Link	pending
xers-20220930.xsd	Edgar Link	pending
xers-20220930_cal.xml	Edgar Link	unprocessable
xers-20220930_lab.xml	Edgar Link	unprocessable
xers-20220930_pre.xml	Edgar Link	unprocessable
xers-20220930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

2022 Q4 Form 10-Q Financial Statement

#000186709622000127 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS Xeris Biopharma Holdings, Inc. Stock $xers

2022 Q4 Form 10-Q Financial Statement

#000186709622000127 Filed on November 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers